Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
Location: United States, Connecticut, New Haven
Employees: 201-500
Total raised: $114.85M
Founded date: 2013
Investors 6
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| - | 5AM Ventur... | 5amventure... |
| - | RA Capital... | racap.com |
| - | Canaan Par... | canaan.com |
| - | Solasta Ve... | solasta-ve... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.04.2018 | Series C | $55M | - |
| 21.10.2015 | Series B | $41.6M | - |
| 26.09.2013 | - | $18.25M | - |
Mentions in press and media 19
| Date | Title | Description |
| 31.05.2025 | Breast cancer: Pfizer-Arvinas drug beats AstraZeneca’s in delaying disease’s progression | - |
| 08.01.2025 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report | Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today ... |
| 09.04.2018 | The biotech, digital health VC to know | Julie Papanek Grant, a partner at Silicon Valley healthcare and tech VC firm Canaan Partners, has managed to check both those boxes in the last couple of years. And while she begs off revealing what her biggest mistake has been and what she... |
| 05.04.2018 | Term Sheet — Thursday April 5 | GOT MONEY Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop The new company is being described as “a mentorship engine that partners with founders to solve core businesses challenges.” In r... |
| 04.04.2018 | Arvinas Completes $55 Million Series C Financing | Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million Series C financing. The financing was led by new investor Nextech Invest, with participati... |
| 04.04.2018 | Arvinas Completes $55M Series C Financing | Arvinas, LLC, a New Haven, Conn.-based biotechnology company creating a new class of drugs based on protein degradation, closed a $55m Series C financing. The round was led by new investor Nextech Invest, with participation from additional ... |
| 04.04.2018 | Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform | - |
| 04.04.2018 | Arvinas gains $55M C round as it eyes cancer trials, pipeline work | Former Fierce 15 winner Arvinas, which has caught the attention of Pfizer and Roche over the last year, has got off a strong $55 million series C as it looks to bring its cancer candidates into the clinic. The New Haven, Conn.-based biotech... |
| 04.04.2018 | Arvinas Completes $55M Series C | NEW HAVEN, CT, Biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million Series C financing. >> Click here for more funding data on Arvinas >> To export Ar... |
| 04.01.2018 | Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease | So what’s attracting the big fish? There are no clinical programs tied up in any of the deals. Instead, they will be drawing on the fruits of Arvinas’s proprietary PROteolysis TArgeting Chimeras (PROTAC) platform. According to a company spo... |
Show more